Journal of Diabetes Investigation (Jul 2022)

Fatty liver with metabolic disorder, such as metabolic dysfunction‐associated fatty liver disease, indicates high risk for developing diabetes mellitus

  • Teruki Miyake,
  • Bunzo Matsuura,
  • Shinya Furukawa,
  • Toru Ishihara,
  • Osamu Yoshida,
  • Masumi Miyazaki,
  • Kyoko Watanebe,
  • Akihito Shiomi,
  • Hironobu Nakaguchi,
  • Yasunori Yamamoto,
  • Yohei Koizumi,
  • Yoshio Tokumoto,
  • Masashi Hirooka,
  • Eiji Takeshita,
  • Teru Kumagi,
  • Masanori Abe,
  • Yoshio Ikeda,
  • Takeru Iwata,
  • Yoichi Hiasa

DOI
https://doi.org/10.1111/jdi.13772
Journal volume & issue
Vol. 13, no. 7
pp. 1245 – 1252

Abstract

Read online

Abstract Introduction Nonalcoholic fatty liver disease (NAFLD) is diagnosed after excluding other liver diseases. The pathogenesis of NAFLD when complicated by other liver diseases has not been established completely. Metabolic dysfunction‐associated fatty liver disease (MAFLD) involves more metabolic factors than NAFLD, regardless of complications with other diseases. This study aimed to clarify the effects of fatty liver occurring with metabolic disorders, such as MAFLD without diabetes mellitus (DM), on the development of DM. Materials and Methods We retrospectively assessed 9,459 participants who underwent two or more annual health check‐ups. The participants were divided into the MAFLD group (fatty liver disease with overweight/obesity or non‐overweight/obesity complicated by metabolic disorders), simple fatty liver group (fatty liver disease other than MAFLD group), metabolic disorder group (metabolic disorder without fatty liver disease), and normal group (all other participants). Results The DM onset rates in the normal, simple fatty liver, metabolic disorder, and MAFLD groups were 0.51, 1.85, 2.52, and 7.36%, respectively. In the multivariate analysis, the MAFLD group showed a significantly higher risk of DM onset compared with other three groups (P < 0.01). Additionally, the risk of DM onset was significantly increased in fatty liver disease with overweight/obesity or pre‐diabetes (P < 0.01). Conclusions Fatty liver with metabolic disorders, such as MAFLD, can be used to identify patients with fatty liver disease who are at high risk of developing DM. Additionally, patients with fatty liver disease complicated with overweight/obesity or prediabetes are at an increased risk of DM onset and should receive more attention.

Keywords